- Home
- IRD vs CATO Comparison
IRD vs CATO Comparison
Compare IRD & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- CATO
- Stock Information
- Founded
- IRD 2018
- CATO 1946
- Country
- IRD United States
- CATO United States
- Employees
- IRD N/A
- CATO N/A
- Industry
- IRD
- CATO Clothing/Shoe/Accessory Stores
- Sector
- IRD
- CATO Consumer Discretionary
- Exchange
- IRD NYSE
- CATO Nasdaq
- Market Cap
- IRD 60.9M
- CATO 55.7M
- IPO Year
- IRD N/A
- CATO N/A
- Fundamental
- Price
- IRD $1.12
- CATO $2.55
- Analyst Decision
- IRD Strong Buy
- CATO
- Analyst Count
- IRD 2
- CATO 0
- Target Price
- IRD $7.00
- CATO N/A
- AVG Volume (30 Days)
- IRD 151.1K
- CATO 43.9K
- Earning Date
- IRD 05-15-2025
- CATO 05-22-2025
- Dividend Yield
- IRD N/A
- CATO 13.28%
- EPS Growth
- IRD N/A
- CATO N/A
- EPS
- IRD N/A
- CATO N/A
- Revenue
- IRD $13,651,000.00
- CATO $642,949,000.00
- Revenue This Year
- IRD $22.00
- CATO N/A
- Revenue Next Year
- IRD $100.89
- CATO N/A
- P/E Ratio
- IRD N/A
- CATO N/A
- Revenue Growth
- IRD N/A
- CATO N/A
- 52 Week Low
- IRD $0.65
- CATO $2.19
- 52 Week High
- IRD $2.18
- CATO $6.70
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- CATO 47.99
- Support Level
- IRD N/A
- CATO $2.50
- Resistance Level
- IRD N/A
- CATO $2.71
- Average True Range (ATR)
- IRD 0.00
- CATO 0.18
- MACD
- IRD 0.00
- CATO -0.00
- Stochastic Oscillator
- IRD 0.00
- CATO 29.44
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.